Comprehensive Genome Profiling for Treatment Decisions in Patients with Metastatic Tumors: Real-World Evidence Meta-Analysis and Registry Data Implementation.

Background: Although precision oncology has rapidly been developed in recent years, its real-world impact and challenges in healthcare implementation remain underexplored. Through a meta-analysis of real-world evidence (RWE), we aimed at investigating the applicability and clinical impact of comprehensive cancer genome profiling (CGP) in cancer patients with metastatic solid tumors.

Methods: We systematically searched Medline, Embase, and Web of Science for RWE studies on CGP and matched therapies in metastatic solid tumors (publication period: 2012-2023).

The treatment interventions and targets of cancer cachexia research during the past decade: a systematic review of the literature.

Background: Cachexia is a detrimental multifactorial syndrome that has been strongly associated with cancer. A growing body of data concerning its management is being generated from the ongoing advances of experimental cancer cachexia research. This study aimed to delineate the broad landscape of cancer cachexia research, by comprehensively presenting the treatment interventions and targets of cancer cachexia during the past decade.

Grading the evidence for physical activity and any outcome in cancer survivors: An Umbrella review of 740 meta-analytic associations.

Background: To contribute to the refinement of future physical activity (PA) guidelines, which have remained mostly generic until now, we performed an umbrella review of meta-analyses for PA in cancer survivors.

Methods: Medline and Scopus databases were searched in January 2024 for systematic reviews and meta-analyses on the association/effect of any type of PA in every cancer type and for any studied outcome. Statistically significant meta-analyses were categorized into four evidence groups (strong, highly suggestive, suggestive, weak) using pre-established grading criteria.

Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236.

The multi-selective tri-complex RAS(ON) inhibitors RMC-7977 and RMC-6236 signal new avenues for RAS targeting. This systematic review aims to comprehensively present the available preclinical and early clinical data on these agents. We screened Medline, Scopus, the ESMO and ASCO conference sites and ClinicalTrials.

Elucidating the non-genetic risk factors for celiac disease: an umbrella review of meta-analyses.

The breadth and validity of the associations of nongenetic risk factors with celiac disease (CeD) are elusive in the literature. We aimed to evaluate which of these associations have strong epidemiological credibility and assessed presence and extent of potential literature biases. We systematically searched PubMed until April 2024 for systematic reviews and meta-analyses of studies examining associations between putative risk factors and CeD.